Longeveron (NASDAQ:LGVN) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen cut shares of Longeveron (NASDAQ:LGVN) from a hold rating to a sell rating in a report released on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings cut shares of Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $80.00.

Longeveron Stock Performance

Shares of LGVN traded down $0.48 during trading hours on Friday, hitting $2.49. 60,383 shares of the stock were exchanged, compared to its average volume of 103,073. The stock’s 50-day moving average price is $2.92 and its two-hundred day moving average price is $6.44. Longeveron has a 12-month low of $1.31 and a 12-month high of $12.30. The company has a market cap of $7.94 million, a price-to-earnings ratio of -0.31 and a beta of -0.09.

Longeveron (NASDAQ:LGVN) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($1.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.70) by ($0.21). Longeveron had a negative net margin of 1,921.72% and a negative return on equity of 209.21%. The firm had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.80 million. On average, research analysts expect that Longeveron will post -7.20 earnings per share for the current year.

Institutional Investors Weigh In On Longeveron

An institutional investor recently bought a new position in Longeveron stock. ADAR1 Capital Management LLC acquired a new position in shares of Longeveron Inc. (NASDAQ:LGVN) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned approximately 0.86% of Longeveron as of its most recent filing with the Securities & Exchange Commission. 10.01% of the stock is currently owned by hedge funds and other institutional investors.

About Longeveron

Longeveron Inc. is a clinical-stage biotechnology company based in Miami, Florida, developing cell-based therapies for serious and age-related conditions. Its research focuses on medicinal signaling cells, a type of adult stem cell that may influence the body’s repair and immune responses. The company’s lead product candidate, Lomecel-B, is an investigational therapy made from donated bone marrow cells. Longeveron has studied it for conditions including hypoplastic left heart syndrome, Alzheimer’s disease and aging-related frailty.